Immune checkpoint inhibitors in esophagogastric cancer: still a long way to go

Immune checkpoint inhibitors (ICIs) targeting the programmed death 1/programmed death-ligand 1 (PD1/PD-L1) pathway have revolutionized treatment for various cancers. Evasion of the immune system is one of the hallmarks of cancer and chronic inflammation can facilitate cancer progression.